CATX Perspective Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NYSEAMERICAN: CATX

Price (delayed)

$2.62

Market cap

$299.08M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.33

Enterprise value

$254.55M

?
Relative Growth: Rel. Growth: 10
Relative Strength: Rel. Strength: 22
Relative Valuation: Rel. Valuation: 1
Relative Profitability: Rel. Profitability: 29

Perspective Therapeutics, Inc. is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha emitting isotope ...

Highlights
Perspective Therapeutics's EPS has increased by 5% from the previous quarter and by 2.2% YoY
CATX's equity is up by 22% year-on-year but it is down by 7% since the previous quarter
The debt has increased by 11% year-on-year but it has declined by 6% since the previous quarter
The revenue has dropped by 67% year-on-year and by 34% since the previous quarter
Perspective Therapeutics's gross profit has plunged by 67% YoY and by 34% from the previous quarter
Sector: Healthcare
Industry: Medical Devices
Website: http://www.isoray.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of CATX

CATX stock price

How has the Perspective Therapeutics stock price performed over time
Intraday
-11.49%
1 week
-2.96%
1 month
-20.61%
1 year
-17.35%
YTD
-4.73%
QTD
-23.17%

Financial performance

How have Perspective Therapeutics's revenue and profit performed over time
Revenue
$409,000
Gross profit
$409,000
Operating income
-$125.23M
Net income
-$116.43M
Gross margin
100%
Net margin
-28,468%
The revenue has dropped by 67% year-on-year and by 34% since the previous quarter
Perspective Therapeutics's gross profit has plunged by 67% YoY and by 34% from the previous quarter
CATX's operating margin has dropped by 58% since the previous quarter
The net margin has dropped by 58% since the previous quarter

Price vs fundamentals

How does CATX's price correlate with its fundamentals

Growth

What is Perspective Therapeutics's growth rate over time

Valuation

What is Perspective Therapeutics stock price valuation
P/E
N/A
P/B
0.92
P/S
772.87
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
622.38
Perspective Therapeutics's EPS has increased by 5% from the previous quarter and by 2.2% YoY
CATX's equity is up by 22% year-on-year but it is down by 7% since the previous quarter
CATX's P/B is 13% below its 5-year quarterly average of 1.2 and 13% below its last 4 quarters average of 1.2
The revenue has dropped by 67% year-on-year and by 34% since the previous quarter
CATX's P/S is 61% above its last 4 quarters average of 542.9

Efficiency

How efficient is Perspective Therapeutics business performance
Perspective Therapeutics's ROS has plunged by 58% from the previous quarter
The ROE has contracted by 28% YoY
The ROA has decreased by 23% YoY
CATX's ROIC is up by 5% YoY

Dividends

What is CATX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CATX.

Financial health

How did Perspective Therapeutics financials performed over time
The company's quick ratio has shrunk by 56% YoY and by 25% QoQ
The current ratio has dropped by 56% year-on-year and by 24% since the previous quarter
The debt is 99% smaller than the equity
CATX's equity is up by 22% year-on-year but it is down by 7% since the previous quarter
The debt has increased by 11% year-on-year but it has declined by 6% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.